pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Sep 22·1 min read
save

Boston life-science lab vacancy climbs to 31% as new spaces sit empty

Sep 22, 2026·read at Fierce Biotech ↗Negative

Vacancy rates for laboratory and manufacturing space in Massachusetts have surged dramatically, rising from around 3% in 2021 to roughly 31% by mid-2026, according to recent data.

One high-profile example is the 10 Prospect tower in Somerville, finished in 2024 with about 200,000 square feet of lab and office area. Despite its modern glass façade, the building’s interior remains largely unfinished, with the ground floor covered in gravel and only a few restaurants operating.

The situation reflects a broader slowdown in the Greater Boston life-science real-estate market, where many newly built facilities are struggling to attract tenants, raising concerns for biotech firms and investors seeking space.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant?”

read at Fierce Biotech ↗
1,965 words · retrieved 20h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AMICUS THERAPEUTICS, INC.2RISING2ASTRAZENECAGENENTECHLEADINGMOUNTAINROCHE
topics
Drug ShortageHematologyOncology

related stories

  • 20h agoCaribou to stop R&D work, start ‘substantial’ job cutsBioSpace
  • Oct 1Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOFierce Biotech
  • Dec 22Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80MFierce Biotech
  • Sep 25Roche's Genentech inks $1.5B bispecific pact with fast-rising EarendilFierce Biotech
  • Sep 9Beyond China: Five other overseas destinations for biopharma dollarsBioSpace